Remission outcomes in severe eosinophilic asthma with mepolizumab therapy : Analysis of the REDES study
Pavord, Ian (University of Oxford)
Gardiner, Frances (GSK House)
Heaney, Liam G. (Queen's University Belfast)
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Price, Robert G. (Biostatistics, GSK)
Pullan, Alison (Plus-Project Partnership Ltd)
Oppenheimer, John (UMDNJ-Rutgers New Jersey Medical School)
Brusselle, Guy (Universitair Ziekenhuis Gent)
Nagase, Hiroyuki (Teikyo University School of Medicine)
Chupp, Geoffrey (Yale Center for Asthma and Airways Disease (YCAAD))
Pizzichini, Emilio (Federal University of Santa Catarina)
Bañas-Conejero, David (GSK)
Howarth, Peter (GSK House)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	Clinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma achieving our multicomponent definitions of clinical remission after 1 year of mepolizumab treatment. The real-world, retrospective observational REDES study enrolled patients with severe eosinophilic asthma who were newly prescribed mepolizumab and with ≥12 months of medical records pre-enrolment. Multicomponent clinical remission was defined as: oral corticosteroid (OCS)-free; exacerbation-free; asthma control test (ACT) score ≥20; and with or without post-bronchodilator forced expiratory volume in 1 second ≥80%. Baseline characteristics were also assessed in those who did/did not achieve clinical remission. 37% and 30% of patients with severe eosinophilic asthma met our proposed three- and four-component on-treatment clinical remission definitions; an increase from 2% and 3% at baseline. Most frequently achieved individual components of clinical remission were: OCS-free; ACT score ≥20. For patients fulfilling the multicomponent clinical remission definitions, at baseline we observed higher blood eosinophil counts, better ACT scores and lung function, lower maintenance OCS use, and a slightly lower rate of prior exacerbations versus those who did not. Clinical remission is a realistic target in clinical practice for a subset of patients with severe eosinophilic asthma receiving mepolizumab. Further studies are required to elucidate whether features linked to the underlying endotype can help predict treatment outcomes, increase rates of clinical remission, and potentially modify disease progression.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Clinical outcomes ; Eosinophil biology ; Mepolizumab ; Remission ; Real-world ; Severe asthma
Published in:	Frontiers in immunology, Vol. 14 (april 2023) , ISSN 1664-3224

DOI: 10.3389/fimmu.2023.1150162
PMID: 37122713

12 p, 3.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles